Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...
Drug
Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...
Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...
InnoCare Pharma Doses First Patient in Phase II/III Trial of TYK2 Inhibitor for Vitiligo
Chinese biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has administered the first patient dose in...
Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...
China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...
FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma
The US Food and Drug Administration (FDA) announced this week an indication extension approval for...
Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...
North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine
China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...
CanSino Biologics Gets Indonesian Approval for Phase I Trial of Inhalable Tuberculosis Vaccine
China-based CanSino Biologics Inc. (HKG: 6185), a specialist in vaccine development, has announced that it...
Haisco Pharma’s HSK21542 Approved by NMPA for Post-Abdominal Surgery Pain
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...
Sihuan Pharmaceutical’s Bireociclib Approved by NMPA for Advanced Breast Cancer
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
CANbridge’s Velaglucerase β Approved by NMPA for Gaucher’s Disease Long-Term Therapy
China-based CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the National Medical Products Administration (NMPA) has...
Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients
Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...
AbbVie’s Emrelis Granted FDA Accelerated Approval for NSCLC with High c-MET Overexpression
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AbbVie’s (NYSE: ABBV)...
Chengdu Kanghong’s KH607 Approved for Clinical Trials in Postpartum Depression
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has announced that it has received...
Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis
Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products...
Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer
Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...
WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure
China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National...
China’s Q1 2025 Pharmaceutical Exports Rise 4.39% Despite Import Decline
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...